<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03967834</url>
  </required_header>
  <id_info>
    <org_study_id>19 SARC 04</org_study_id>
    <nct_id>NCT03967834</nct_id>
  </id_info>
  <brief_title>Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group</brief_title>
  <acronym>MIRAS</acronym>
  <official_title>Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to draw an &quot;immune landscape profiling&quot; of all SARRA (&quot; SARcomes
      RAres &quot;) subtypes in order to identify new innovative therapeutic strategies for these
      sarcomas. The impact of different factors (the transcriptomic signature CINSARC (Complexity
      Index in SARComas), the tumor infiltration of immune populations and the Cancer-Testis
      Antigens (CTA) expression) on tumour behaviour and clinical outcome will be studied.

      More than 500 tumours will be analysed for the study.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2019</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cancer-Testis Antigens (CTA) expression</measure>
    <time_frame>36 months for all patients</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of patients presenting high-risk CINSARC (Complexity Index in SARComas) signature</measure>
    <time_frame>36 months for all patients</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Soft Tissue Sarcoma</condition>
  <condition>Clear Cell Sarcoma</condition>
  <condition>Epithelioid Sarcoma</condition>
  <condition>Perivascular Epithelioid Cell Neoplasms</condition>
  <condition>Desmoplastic Small Round Cell Tumor</condition>
  <condition>Solitary Fibrous Tumors</condition>
  <condition>Alveolar Soft Part Sarcoma</condition>
  <condition>Epithelioid Hemangioendothelioma</condition>
  <condition>Low Grade Fibromyxoid Sarcoma</condition>
  <condition>Sclerosing Epithelioid Fibrosarcoma</condition>
  <arm_group>
    <arm_group_label>Patient with Soft Tissue Sarcoma</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patient with Soft Tissue Sarcoma</intervention_name>
    <description>Tumor specimens will be collected for the study at diagnosis.
Clinical data (patients and tumour characteristics) will be collected during the study for each patient included.</description>
    <arm_group_label>Patient with Soft Tissue Sarcoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Prospective and incident case of Soft Tissue Sarcoma (Clear Cell Sarcoma, Epithelioid
             Sarcoma, Perivascular Epithelioid Cell neoplasm, Desmoplastic Small Round Cell
             Tumours, Solitary Fibrous Tumours, Alveolar Soft Part Sarcoma, Epithelioid
             Haemangioendothelioma, Low-Grade Fibromyxoid Sarcoma and Sclerosing Epithelioid
             Fibrosarcoma)

          2. Signed written informed consent

          3. Patient affiliated to a Social Health Insurance in France

        Exclusion Criteria:

          1. Any psychological, familial, geographic or social situation, according to the judgment
             of investigator, potentially preventing the provision of informed consent or
             compliance to study procedure.

          2. Patient who has forfeited his/her freedom by administrative or legal award or who is
             under guardianship.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thibaud VALENTIN</last_name>
    <phone>+33 (0)5 31 15 51 70</phone>
    <email>Valentin.Thibaud@iuct-oncopole.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frédéric CHIBON</last_name>
    <phone>+33 (0)5 82 74 17 65</phone>
    <email>frederic.chibon@inserm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer Toulouse - Oncopole</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Thibaud VALENTIN</last_name>
      <phone>+33 (0)5 31 15 51 70</phone>
      <email>Valentin.Thibaud@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 27, 2019</study_first_submitted>
  <study_first_submitted_qc>May 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2019</study_first_posted>
  <last_update_submitted>May 27, 2019</last_update_submitted>
  <last_update_submitted_qc>May 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Soft Tissue Sarcoma</keyword>
  <keyword>Clear Cell Sarcoma</keyword>
  <keyword>Epithelioid Sarcoma</keyword>
  <keyword>Perivascular Epithelioid Cell Neoplasms</keyword>
  <keyword>Desmoplastic Small Round Cell Tumor</keyword>
  <keyword>Solitary Fibrous Tumors</keyword>
  <keyword>Alveolar Soft Part Sarcoma</keyword>
  <keyword>Epithelioid Hemangioendothelioma</keyword>
  <keyword>Low Grade Fibromyxoid Sarcoma</keyword>
  <keyword>Sclerosing Epithelioid Fibrosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Desmoplastic Small Round Cell Tumor</mesh_term>
    <mesh_term>Fibrosarcoma</mesh_term>
    <mesh_term>Sarcoma, Alveolar Soft Part</mesh_term>
    <mesh_term>Sarcoma, Clear Cell</mesh_term>
    <mesh_term>Hemangioendothelioma</mesh_term>
    <mesh_term>Neoplasms, Fibrous Tissue</mesh_term>
    <mesh_term>Solitary Fibrous Tumors</mesh_term>
    <mesh_term>Hemangioendothelioma, Epithelioid</mesh_term>
    <mesh_term>Perivascular Epithelioid Cell Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

